Search CORT
CORCEPT THERAPEUTICS INC
Nasdaq · CIK 1088856
Last close116.23
Daily change+2.20 (1.93%)
10 Years gain+1639.97%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CORT · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
53.2Momentum
0.0Acceleration
0.0Confidence
83.0Annual Revenue15
Quarterly Revenue61
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.7 / 25
Quality9.4 / 25
Capital Efficiency1.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics7.1 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 1.1968%.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 14.225 percentage points.
ROIC declining · MEDIUMROIC declined by 28.0488 percentage points.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM26.56%OK
Revenue CAGR 3Y23.74%OK
Gross Margin98.18%OK
Operating Margin3.47%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC4.38%OK
Incremental Operating Margin 3Y-22.31%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-1.2%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $761.41M | $748.43M | $44.80M | $142.00M | $141.79M | 98.3% | 5.88% | 18.62% | 10.18% | 119.99M |
| 2025 FY Dec 31, 2024 | $675.04M | $664.16M | $136.95M | $198.30M | $196.12M | 98.39% | 20.29% | 29.05% | 55.09% | 113.48M |
| 2025 FY Dec 31, 2023 | $482.38M | $475.89M | $107.28M | $126.68M | $126.54M | 98.66% | 22.24% | 26.23% | 87.63% | 111.74M |
| 2024 FY Dec 31, 2022 | $401.86M | $396.47M | $112.63M | $120.32M | $119.91M | 98.66% | 28.03% | 29.84% | 88.39% | 115.97M |
| 2023 FY Dec 31, 2021 | $365.98M | $360.70M | $124.48M | $167.89M | $167.42M | 98.56% | 34.01% | 45.75% | 95.39% | 125.96M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $823.12M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-050613, 0001628280-25-048841 |
| Revenue Growth TTM | 26.56% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-050613, 0001628280-25-048841 |
| Revenue CAGR 3Y | 23.74% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011091 |
| Revenue CAGR 5Y | 16.56% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-011091 |
| Gross Profit CAGR 3Y | 23.59% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-011091 |
| Operating Income Growth | -75.16% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001628280-26-050613, 0001628280-25-048841 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 98.18% | Gross Profit / Revenue | OK | 0001628280-26-050613, 0001628280-25-048841 |
| Operating Margin | 3.47% | Operating Income / Revenue | OK | 0001628280-26-050613, 0001628280-25-048841 |
| ROIC | 4.38% | NOPAT / Average Invested Capital | OK | 0001628280-26-050613, 0001628280-25-048841 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-050613 |
| Current Ratio | 2.86x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $6.95 | Revenue / Diluted Shares | OK | 0001628280-26-050613, 0001628280-25-048841 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |